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Abstract
Background: Diabetes is a global, growing and costly public health problem. In the literature, there are conflicting
reports on the effect of consumption of bee honey on diabetes. We assessed the possible effect of a commercially
available bee honey (given orally by gavage at doses of 1 g/kg/day for 4 weeks) on the blood concentrations of
glucose, insulin and leptin and body weight of rats with streptozotocin-induced diabetes.
Methods: Thirty-six rats were allocated randomly into six groups equally and treated for 4 weeks as follows: Group.
1: non-diabetic rats given distilled water, group.2: non-diabetic rats given honey (1 g/kg), group.3: Diabetic rats
given distilled water, group.4: Diabetic rats given honey, group.5: Diabetic rats given insulin (10 IU/kg), and group.6:
Diabetic rats given combination of insulin (10 IU/kg) with honey (1 g/kg). The body weight, blood glucose, insulin
and leptin concentrations of each rat were measured.
Results: Honey treatment did not significantly affect the glucose, leptin and insulin concentrations of diabetic rats.
It did not significantly affect the excessive water intake or urinary output in diabetic rats when compared to the
insulin-treated groups. Neither honey nor insulin improved body weight in diabetic rats.
Conclusion: Contrary to the reports of a salutary effect of honey in diabetic humans and rodents, our results
showed that consumption of honey caused no significant changes in body weight, or glucose and insulin
concentrations. However, further studies with different doses and durations of treatment are warranted.
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Background
Diabetes is an abnormal metabolic state that results in
hyperglycemia due to either insulin deficiency or abnormal
response to insulin, and is of two types: type I, which is
caused by severe deficiency in insulin synthesis, and type II
diabetes that is complicated with insulin resistance and/or
insulin production deficiency [1]. In 2014, it has been
estimated that there are about 387 million diabetic patients
worldwide [2]. Consequently, studies conducted to find out
an ideal remedy against diabetes are needed, and bee honey
has been suggested as one of these [3, 4].
Bees honey from bees (Apis mellifera) is produced
from nectar and it consists of at least 181components
including fructose (37.5%), glucose (30.6%), sucrose
(1.62%), maltose (2.7%), water (17.2%), vitamins, min-
erals, enzymes, acids such as flavonoids, phenolic acids
and other components [3–9]. Honey’s constituents differ
slightly depending on the botanical species [10, 11].
In folk medicine, honey is used in different parts of the
world for a number of unrelated diseases and conditions
[5]. Furthermore, it is known to possess antioxidant, anti-
inflammatory and antimicrobial properties [4, 11–13].
Moreover, it has been reported that honey has effects
against hyperglycemia in diabetic patients and against
complications of diabetes. Its anti-hyperglycemic effects
may relate to its fructose content and antioxidant proper-
ties [4, 6]. Fructose is a monosaccharide sugar that has
slow absorption rate and its intake may lead to delaying
the digestion and elongating the gastric emptying. There-
fore, the fructose was suggested to contribute to the anti-
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hyperglycemic effects of the honey. Some studies showed
that fructose increases hepatic uptake of glucose resulting
in decreasing blood glucose [4]. The antioxidant effects of
honey may be due to compounds such as flavonoids and
phenolic acids [5, 14–16]. These antioxidants activities of
honey may improve oxidative stress in β-cells in the
pancreas, and this may lead to promoting insulin secre-
tion. In addition, honey has been found to reduce insulin
resistance in type II diabetic patients [17].
In literature, many parameters were used to investigate
glycemic control of diabetic patients/animals including
blood glucose, body weight, HbA1c and others. Moreover,
many other parameters (eg insulin and leptin) were sug-
gested to be used as indicators or predictors for diabetes
status or its glycemic control. There is a controversy re-
garding the association between leptin levels & diabetes.
However, it has been reported that blood leptin levels may
be used as a predictor for glycemic control [18]. Moreover,
Japanese researchers investigated the possible therapeutic
effects of leptin in congenital hyperleptinemic diabetic
mice models where it showed a salutary effect [19]. Many
studies were conducted to find out the effect of honey on
diabetic rats in which they investigated blood insulin level
and their results were variable [20–22].
In literature, there is a controversy regarding the antihy-
perglycemic effects of honey on diabetes. Therefore, our
study aimed to assess the effect of a commercially available
bee honey (1 g/kg/day for 4 weeks) on the concentrations
of blood glucose, insulin and leptin and body weight in nor-
mal rats and rats with streptozotocin-induced diabetes.
Methods
Animal models
This prospective randomized controlled study was carried
at Sultan Qaboos University in Muscat, Oman between
January 2013 and July 2014. The use of rats and all the
experimental procedures were approved by the Animal
Ethical Committee at Sultan Qaboos University (SQU/
ACE/2012-13/4). Thirty six female Sprague Dawley rats
(250–350 g) were obtained from Small Animal House of
Sultan Qaboos University, Muscat, Oman and were kept
under standard conditions (a temperature of 22 ± 2 °C, rela-
tive humidity of about 60%, with a 12 h light–dark cycle
(lights on 6:00), and (unless otherwise mentioned) given
free access to standard pellet chow diet containing 0.85%
phosphorus, 1.12% calcium, 0.35% magnesium, 25.3% crude
protein and 2.5 IU/g vitamin D3 (Oman Flour Mills,
Muscat, Oman) and water. Ethical clearance was obtained
from our University Animal Ethics Committee and all
procedures involving animals and their care were carried
out in accordance with international laws and policies (EEC
Council directives 86/609, OJL 358, 1 December, 12, 1987;
NIH Guide for the Care and Use of Laboratory Animals,
NIH Publications No. 85-23, 1985).
Induction of diabetes
Diabetes was induced after 18 h fasting by intraperitoneal
(i.p.) injection of streptozotocin (STZ) at a dose of 50 mg/kg,
dissolved in 0.1 M of a citrate buffer (pH 4.5) [23]. Other
groups of rats were injected with citrate buffer. Two days
thereafter, the blood glucose (BG) concentration was checked
using a OneTouch® UltraMini® Meter (LifeScan, Milpitas,
CA, USA) using a drop of blood obtained by pricking tip tail.
Rats with blood glucose concentrations≥ 14 mmol/L were
considered diabetic [12]. Treatments were started 3 weeks
after STZ or citrate buffer injections. Body weight was mea-
sured daily, fasting blood glucose concentration was mea-
sured weekly, and blood insulin & leptin concentrations were
measured once at the end of the experiment.
Experimental design
The animals were allocated randomly into six equal groups
and treated for 4 weeks as follows: Group1 (C): non-diabetic
and were treated via oral gavage with distilled water (0.5 ml/
rat) via oral gavage once daily; Group 2 (H): non-diabetic
and were given honey (1 g/kg body weight) via oral gavage
once daily [12, 20, 24]; Group 3 (D): diabetic and were
treated with distilled water (0.5 ml/rat) via oral gavage once
daily; Group 4 (DH): diabetic and were treated with honey
(1 g/kg body weight) via oral gavage once daily; Group 5
(DI): diabetic and were treated with insulin (10 IU/Kg body
weight) subcutaneously once daily [25]; and Group 6 (DIH):
diabetic and were treated with honey (1 g/kg body weight)
and insulin (10 IU/Kg body weight) once daily.
After 4 weeks of treatment, rats were placed in metabolic
cages to measure water intake & collect 24-h urine. Fasting
Blood glucose concentration was measured and rats were
then anesthetized (using ketamine (75 mg/kg) and xylazine
(5 mg/kg) intraperitoneally) and blood (4 ml) collected
from the inferior vena cava. Blood samples were centri-
fuged (900 g for 15 min at 4 °C) and plasma collected was
frozen for subsequent measurement of leptin and insulin
concentrations.
Commercially available honey (Golden Glory, Australia)
was bought from a local market in Muscat. Honey (1 g/
kg/day) was diluted with distilled water before given it to
the rats by gavage. As well as, Insulin (10 IU/Kg body
weight) was diluted with 0.90% NaCl just before injecting.
Biochemical analysis
Collected plasma samples were analyzed using ELISA test
for both insulin (EIA Kit, Gayman Chemical Company,
Michigan, USA) and leptin (EIA Kit, Gayman Chemical
Company, Michigan, USA).
Statistical analysis
Statistical analysis was conducted by the GraphPad Prism
6.0 (GraphPad Software, San Diego, CA, USA). Each group
consisted of six rats. All data are given as means ± S.E.M.
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Group means were compared with an analysis of variance
(ANOVA; One-Way) followed by Tukey’s multiple com-
parison test. Values of P < 0.05 were considered significant.
Results
Figure 1 summarizes the results of 24 h water intake and
urine output of six different groups of rats. The diabetic
control animals had significantly (p < 0.01) increased
water intake compared to non-diabetic control rats.
Commercial honey significantly increased water intake
in both diabetic group which given honey (p < 0.01) and
diabetic group that treated with insulin in combination
with honey (p < 0.05) compared to non-diabetic control
rats. However, water intake of diabetic rats that received
honey showed no significant difference compared to
diabetic control rats. The diabetic control group and dia-
betic that treated with honey had significantly (p < 0.05)
higher water intake compared to non-diabetic that re-
ceived honey.
Urine output of the diabetic control group was signifi-
cantly (p < 0.05) higher than non-diabetic control. The
diabetic group that treated with honey alone showed sig-
nificant increase in urine output compared to non-diabetic
control (p < 0.0001) and non-diabetic that received honey
(p < 0.001). Moreover, diabetic with insulin and diabetic
that treated with insulin in combination with honey showed
significant decrease in urine output compared to diabetic
with honey (p < 0.01).
Table 1 shows the effects of 4 weeks treatment with
honey or insulin, or their combination on body weight of
treated rats. There was initially no significant difference in
the body weight among all the groups. After induction of
diabetes, the groups that injected with streptozotocin had
significantly lower body weight compared to the two non-
diabetic groups. After starting the treatment of animals,
neither honey nor insulin showed a significant improve-
ment in body weight of diabetic rats compared to non-
diabetic rats. However, the animals that treated with insulin
or a combination of insulin and honey had significantly
higher body weight in the fourth week of treatment com-
pared to diabetic group that received honey alone (p <
0.01). Along the period of treatment, there was no signifi-
cant difference between the diabetic group that given honey
and the diabetic control group.
Table 2 summarizes the effects of 4 weeks treatment of
honey and insulin or their combination on fasting serum
blood glucose concentration of six different groups of rats.
Before injecting the rats with streptozotocin, there was no
significant difference in fasting blood glucose concentration
among the six groups of the animals. The rats that treated
with streptozotocin showed a significant increase in blood
glucose concentration in the weeks before the treatment
compared to both non-diabetic control group (4.25 ± 0.25)
& non-diabetic treated with honey group (4.98 ± 0.22). The
diabetic animals that received honey had no significant
increase in the blood glucose concentration compared to
diabetic control rats. However, diabetic control rats &
diabetic rats that given commercial honey had significantly
higher blood glucose concentration compared to the two
non-diabetic groups along the duration of treatment. Along
the 4 weeks of treatment, the rats that treated with insulin
showed no significant difference in fasting blood glucose
concentration (11.65 ± 2.43, 5.95 ± 0.85, 13.78 ± 4.46, &
8.33 ± 2.15 respectively) compared to non-diabetic control
group (5.13 ± 0.24, 4.02 ± 0.10, 4.00 ± 0.22, & 4.82 ± 0.21 re-
spectively) & non-diabetic group that given honey (5.00 ±
0.22, 4.16 ± 0.09, 3.88 ± 0.11, & 4.90 ± 0.16 respectively). In
contrast, there was a significant difference between diabetic
rats that given insulin on one side and the diabetic control
or the diabetic that treated with honey on the other side in
most of the weeks of the treatment. The diabetic group that
received the combination of honey and insulin had no sig-
nificant increase in blood glucose concentration compared
Fig. 1 Effect of honey on (a) water intake and (b) urine output in
normal and diabetic rats. Data are expressed as mean ± SEM. Each
group consisted of four to six rats. Values are significant at * p < 0.05,
** p < 0.01, **** p < 0.0001 compared to C; # p < 0.05, ### p < 0.001
compared to H; ΨΨ p < 0.01 compared to DH
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to the two non-diabetic groups among second, third and
fourth week of treatment.
Figure 2 shows the effects of 4 weeks treatment with
honey or insulin, or their combination on blood (a) insulin
& (b) leptin concentrations. Overall, honey treatment did
not show any significant change in blood insulin concentra-
tion among all groups of rats. However, diabetic rats treated
with honey in combination with insulin showed significant
decrease (p < 0.05) in blood insulin concentration com-
pared to non-diabetic that received honey as shown in
graph (a) in Fig. 2.
The diabetic control group had significantly (p < 0.01)
lower blood leptin concentration compared to non-diabetic
control rats and non-diabetic group that received honey
alone. There is no significant difference between non-
diabetic groups and diabetic groups that received honey,
insulin or their combination (ie honey improved leptin
blood concentration).
Discussion
In the current study, we found that honey treatment did
not significantly prevent excessive water intake and urinary
frequency in diabetic rats. However, in rats treated with
insulin, there were improvements in these two physiological
parameters. As far as we are aware, there are no previously
reported data on the effects of honey and insulin (given
together) on water intake and urine output.
As expected, significant decrease in body weight was
observed in STZ-induced diabetic rats, and this may be
because of connective tissue degradation due to the surge
lysosomal activity [26]. Our study showed that neither
honey nor insulin improved the loss in body weight in-
duced by diabetes when compared to non-diabetic rats. In
contrast, some previous studies had reported that honey
has a beneficial effect in increasing the body weight of the
diabetic humans and rats probably due to the fructose
component of honey with its purported antihyperglycemic
effects [12, 20]. Diabetic rats that were treated with insulin
showed body weight gain and this may be due to the effect
of insulin in decreasing energy loss via urine [25].
Unlike our present results, some authors in Malaysia
[12, 20] reported that the honey they used in their experi-
ments was effective in ameliorating streptozotocin - in-
duced diabetes in rats because honey has anti-oxidant
properties against streptozotocin – induced oxidative
stress, which leads to β cells destruction. Fructose in the
honey may also slows the absorption rate which may lead
to delaying the digestion and elongating the gastric
emptying and its ability to increase hepatic uptake of glu-
cose resulting in decreasing blood glucose [4]. The
Table 1 The effect of honey on body weight of normal and diabetic rats
Group Control Diabetic Honey Diabetic + Honey Diabetic + Insulin Diabetic + Insulin + Honey
A week before
treatment
302.00 ± 4.95 241.17 ± 12.08 ** ## 303.00 ±
13.92
233.17 ± 12.32 ** # # 242.00 ± 10.61* # 261.60 ± 6.86
Weeks after treatment
1st 307.50 ± 5.80 230.00 ± 13.68*** ## 300.60 ±
13.71
220.00 ± 12.25****
###
241.25 ± 16.18** # 252.20 ± 6.15*
2nd 328.50 ± 6.16 260.00 ± 14.76** # 322.00 ±
15.43
238.17 ± 14.43*** ## 252.25 ± 16.62** # 251.20 ± 5.44** ##
3rd 327.83 ± 6.80 239.17 ± 14.08**** ### 323.60 ±
13.82
224.67 ± 8.83****
####
253.50 ± 16.81** ## 251.00 ± 7.12** ##
4th 324.83 ± 6.16 202.33 ± 14.44 ***
####
324.00 ±
12.35
182.33 ± 14.37 ***
###
256.25 ± 17.72 * #
ΨΨ
250.60 ± 6.59 ** ## ΨΨ
Data are expressed as mean ± SEM (n= 4–6 rats). Values are significant at *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001 compared to C; #p< 0.05, ##p< 0.01, ###p< 0.001,
####p< 0.0001 compared to H;ΨΨp< 0.01 compared to DH
(Location: can be added after the second page of the results section)
Table 2 The effect of honey on blood glucose concentration in the blood of normal and diabetic rats
Group Control Diabetic Honey Diabetic + Honey Diabetic + Insulin Diabetic + Insulin + Honey
A week before treatment 4.25 ± 0.25 13.07 ± 2.48 4.98 ± 0.22 19.60 ± 3.57 ** ## 17.60 ± 3.25 * # 25.74 ± 2.28 **** $ ####
Weeks after treatment
1st 5.13 ± 0.24 23.85 ± 0.83 **** ### 5.00 ± 0.22 22.72 ± 3.90 *** ### 11.65 ± 2.43 $ 17.30 ± 4.00 * #
2nd 4.02 ± 0.10 14.20 ± 3.55 4.16 ± 0.09 15.08 ± 2.86 5.95 ± 0.85 13.80 ± 4.52
3rd 4.00 ± 0.22 19.05 ± 3.52 ** ## 3.88 ± 0.11 26.37 ± 2.35 **** #### 13.78 ± 4.46 Ψ 15.40 ± 3.59
4th 4.82 ± 0.21 21.55 ± 2.97 *** ## 4.90 ± 0.16 22.52 ± 3.72 *** ### 8.33 ± 2.15 $, Ψ 11.48 ± 2.77 Ψ
Data are expressed as mean ± SEM (n= 4–6 rats). Values are significant at *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001 compared to C; #p< 0.05, ##p< 0.01, ###p< 0.001,
####p< 0.0001 compared to H; $p< 0.05 compared to D; Ψp< 0.05 compared to DH
(Location:can be added in the page after that of Table 1)
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antioxidant effects of honey may be attributed to its flavo-
noids and phenolic acids contents, which decrease the free
radicals in β-cells in the pancreas, and this may lead to
promoting insulin secretion [5, 14–16]. However, Bahrami
and his colleagues reported that honey had no significant
difference in blood glucose concentration of diabetic pa-
tients with type 2 diabetes. When honey used to treat dia-
betic rats, they showed no improvement in blood glucose
concentration [27].
It is not clear why we could not reproduce the positive
results of those who claim honey is beneficial in diabetic
rats [12, 20]. The discrepancy may be due to the type of
honey used in both experiments. It is known that the
composition of honey depends on its floral origin, or to
other unknown factors [10, 11].
Plasma insulin concentration is usually significantly re-
duced in rats with streptozotocin – induced diabetes [28].
However, we found that there is no significant difference in
blood insulin concentration among all groups except for
diabetic rats given honey in combination with insulin and
non-diabetic group given honey. Many studies were con-
ducted to find out the effect of honey on diabetic rats and
their results were at variance. Some authors found that
honey increases the concentration of insulin concentration
but the others showed that honey had no effect on blood
insulin concentration [20–22]. Our results seem to insig-
nificantly inceases the plasma concnetrations of insulin.
Leptin is a protein hormone mainly produced by adi-
pocytes and plays a vital role in the regulation of energy
intake and expenditure, and is positively associated with
body mass index (BMI) and the absolute fat mass, as
well as glycemic control [29]. The recent study showed
that honey increased leptin blood concentration of dia-
betic rats given honey, insulin or their combination
compared to diabetic control group. Many studies were
conducted to investigate the association between leptin
and diabetes and their results were contradicted. Some
studies showed that there is a direct association between
leptin and diabetes development [30–33]. On the other
hand, other studies found that there is no association be-
tween leptin and diabetes [34, 35]. A randomized control
trial on rats showed that the rats treated with honey
have lower blood leptin concentration compared to
those treated with sucrose [22].
The possible limitations of this experiment are the
small number of rats in each group and the use of a sin-
gle type of honey at a single dose. Further experiments
using different types of honey at different doses against
streptozotocin-induced diabetes are warranted.
Conclusion
Based on our results, the present preliminary experiment
suggests that the use of honey as a possible treatment in
streptozotocin-induced diabetes in rats is not beneficial.
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